- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | eXoZymes reports Q1 results | 2 | Seeking Alpha | ||
| Mo | eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today | 222 | ACCESS Newswire | Management to host earnings call at 5:00PM Eastern Time, today. MONROVIA, CA / ACCESS Newswire / May 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that... ► Artikel lesen | |
| Mo | EXOZYMES INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| EXOZYMES Aktie jetzt für 0€ handeln | |||||
| 07.05. | eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST | 236 | ACCESS Newswire | MONROVIA, CA / ACCESS Newswire / May 7, 2025 / eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines,... ► Artikel lesen | |
| 06.05. | eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health | 237 | ACCESS Newswire | N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier... ► Artikel lesen | |
| 25.04. | EXOZYMES INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 21.04. | eXoZymes Inc.: Bringing clarity and precision to the cell-free space by introducing exozymes | 1 | GlobeNewswire (USA) | ||
| 14.04. | New to The Street's FOX Business "Late Night T.V." Special Airs Tonight - Show #650 - Featuring Health In Tech CEO Julia Qian , BioVie's Dr. Joseph Palumbo , eXoZymes Co-Founder & VP of Research Tyler Korman , and ARRIVE AI Founder & CEO Dan O'Toole | 341 | ACCESS Newswire | Also debuting - our hospitality segment featuring BLACKBARN NYC with Chef John Doherty and a spotlight on The Sustainable Green Team (OTC PINK:SGTM) with Kevin Harrington and CEO Tony Raynor NEW YORK... ► Artikel lesen | |
| 12.04. | New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presiden | 803 | ACCESS Newswire | New to The Street debuts its inaugural restaurant segment featuring BlackBarn with owner and chef John Doherty NEW YORK CITY, NY / ACCESS Newswire / April 12, 2025 / New to The Street, a leading financial... ► Artikel lesen | |
| 11.04. | New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie's Dr. Joe Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President T | 483 | ACCESS Newswire | BlackBarn Restaurant NYC on 26th street The premiere restaurant segment with Owner and Head Chef John Doherty NEW YORK CITY, NEW YORK / ACCESS Newswire / April 11, 2025 / New to The Street, a leading... ► Artikel lesen | |
| 11.04. | New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presiden | 368 | ACCESS Newswire | New Segment "Market Bites" Debuts with Chef John Doherty of BlackBarn Showcasing the Culinary Side of Business Leadership NEW YORK CITY, NEW YORK / ACCESS Newswire / April 11, 2025 / New to The Street... ► Artikel lesen | |
| 10.04. | eXoZymes Inc.: BioClick - an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant | 2 | GlobeNewswire (USA) | ||
| 02.04. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.04. | eXoZymes appoints new chief commercial officer | 1 | Investing.com | ||
| 02.04. | eXoZymes GAAP EPS of -$0.89 | 2 | Seeking Alpha | ||
| 02.04. | eXoZymes Inc.: eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO | 108 | GlobeNewswire (Europe) | Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus... ► Artikel lesen | |
| 02.04. | eXoZymes Inc.: eXoZymes Provides Fourth Quarter and Full Year 2024 Update | 203 | GlobeNewswire (Europe) | Management to Host Conference Call Today at 4:30PM Eastern Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that... ► Artikel lesen | |
| 31.03. | EXOZYMES INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 29.03. | New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. | 793 | ACCESS Newswire | Sponsored by The Sustainable Green Team (OTC: SGTM), featuring Kevin Harrington - the ORIGINAL Shark from Shark Tank NEW YORK CITY, NEW YORK / ACCESS Newswire / March 29, 2025 / New to The Street, the... ► Artikel lesen | |
| 24.03. | New to The Street's FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese's The Big Skinny on eXoZymes, and Banzai CEO Joe Dav | 441 | ACCESS Newswire | Sponsored by The Sustainable Green Team and Featuring an Exclusive Interview with Former Shark Kevin Harringtonhttps://www.youtube.com/watch?v=EfMWKXgIqrINEW YORK CITY, NY / ACCESS Newswire / March... ► Artikel lesen |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 3,094 | +2,04 % | CureVac Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| VALNEVA | 2,810 | -2,63 % | Valneva: Aktie trotzt negativen News | Die Aktie von Valneva kann sich auch zum Wochenstart gut behaupten. Trotz negativer News zum Chikungunya-Impfstoff IXCHIQ ist das Papier im Tagesverlauf auf der Handelsplattform Tradegate ins Plus gedreht.... ► Artikel lesen | |
| EPIGENOMICS | 0,980 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| NOVAVAX | 5,607 | +5,16 % | Novavax springt kräftig an - Quartalszahlen pulverisiert | Der US-Biotechkonzern Novavax hat am Donnerstagnachmittag seine Quartalszahlen vorgelegt und die Erwartungen der Analysten um Längen geschlagen. Vor allem bei dem Gewinn pro Aktie gab es eine enorm... ► Artikel lesen | |
| 4SC | 2,690 | +4,26 % | PTA-Adhoc: 4SC AG: 4SC gibt weiteres Feedback der EMA zum Zulassungsantrag von Resminostat (Kinselby) bekannt | DJ PTA-Adhoc: 4SC AG: 4SC gibt weiteres Feedback der EMA zum Zulassungsantrag von Resminostat (Kinselby) bekannt
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
4SC AG: 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,100 | +35,49 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 08.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.05.2025.ISIN NameGB00BYQ94H38 ONCIMMUNE... ► Artikel lesen | |
| AAP IMPLANTATE | 1,230 | +4,24 % | EQS-News: aap Implantate AG: aap startet stabil ins Geschäftsjahr 2025 - Wachstum in der umsatzstärksten Region EMEA | EQS-News: aap Implantate AG
/ Schlagwort(e): Quartals-/Zwischenmitteilung
aap startet stabil ins Geschäftsjahr 2025 - Wachstum in der umsatzstärksten Region EMEA
06.05.2025... ► Artikel lesen | |
| BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| VIVOSIM LABS | 1,930 | +1,05 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,396 | +1,02 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants... ► Artikel lesen | |
| MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - F-1/A, Registration statement for certain foreign private issuers | ||
| INFLARX | 1,602 | -1,72 % | Raymond James maintains Strong Buy on Inflarx stock, $13 target | ||
| INTELLIA THERAPEUTICS | 7,148 | +1,36 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress | On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,780 | -8,55 % | COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update | Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures... ► Artikel lesen | |
| VAXART | 0,369 | +1,15 % | Vaxart, Inc.: Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial | SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority... ► Artikel lesen |
EXOZYMES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,42 % bei einem Aktienkurs von 14,210 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXOZYMES INC finden Sie auf Wallstreet Online.